Raras
Buscar doenças, sintomas, genes...
Síndrome Alport
ORPHA:63CID-10 · Q87.8CID-11 · LD2H.YDOENÇA RARA

Doença renal rara caracterizada por nefropatia glomerular com hematúria progredindo para doença renal em estágio terminal (DRT), frequentemente associada à surdez neurossensorial e, ocasionalmente, a anomalias oculares.

Mantido por Agente Raras·Colaborar como especialista →

Introdução

O que você precisa saber de cara

📋

Doença renal rara caracterizada por nefropatia glomerular com hematúria progredindo para doença renal em estágio terminal (DRT), frequentemente associada à surdez neurossensorial e, ocasionalmente, a anomalias oculares.

Pesquisas ativas
15 ensaios
38 total registrados no ClinicalTrials.gov
Publicações científicas
1.971 artigos
Último publicado: 2026 Apr
Medicamentos
6 registrados
HYDROXYCHLOROQUINE, BENAZEPRIL, VALSARTAN

Tem tratamento?

6 medicamentos registrados
Ver detalhes, fases e interações →
HYDROXYCHLOROQUINEBENAZEPRILVALSARTANBARDOXOLONE METHYLFLUVASTATINELX-02

Escala de raridade

CLASSIFICAÇÃO ORPHANET · BRASIL 2024
Unknown
Ultra-rara
<1/50k
Muito rara
1/20k
Rara
1/10k
Pouco freq.
1/5k
Incomum
1/2k
Prevalência
0.0
Europe
Início
Adolescent
+ adult, childhood, elderly
🏥
SUS: Cobertura mínimaScore: 15%
CID-10: Q87.8
🇧🇷Dados SUS / DATASUS
PROCEDIMENTOS SIGTAP (5)
0202010503
Cariótipo — bandas G, Q ou Rgenetic_test
0202010600
Pesquisa de microdeleções/microduplicações por FISHlab_test
0202010694
Sequenciamento completo do exoma (WES)rehabilitation
0202010260
Dosagem de alfa-fetoproteína
0301070040
Atendimento em reabilitação — doenças raras
Você se identifica com essa condição?
O Raras está aqui pra te apoiar — com ou sem diagnóstico

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Entender a doença

Do básico ao detalhe, leia no seu ritmo

Preparando trilha educativa...

Sinais e sintomas

O que aparece no corpo e com que frequência cada sintoma acontece

Partes do corpo afetadas

🫘
Rins
17 sintomas
👁️
Olhos
10 sintomas
🫁
Pulmão
3 sintomas
👂
Ouvidos
3 sintomas
🧠
Neurológico
2 sintomas
🫃
Digestivo
2 sintomas

+ 13 sintomas em outras categorias

Características mais comuns

90%prev.
Hematúria
Muito frequente (99-80%)
90%prev.
Laminação difusa da membrana basal glomerular
Muito frequente (99-80%)
90%prev.
Membrana basal glomerular fina
Muito frequente (99-80%)
55%prev.
Insuficiência renal
Frequente (79-30%)
55%prev.
Hipertensão
Frequente (79-30%)
55%prev.
Hipercelularidade mesangial
Frequente (79-30%)
55sintomas
Muito frequente (3)
Frequente (4)
Ocasional (18)
Muito raro (13)
Sem dados (17)

Os sintomas variam de pessoa para pessoa. Abaixo estão as 55 características clínicas mais associadas, ordenadas por frequência.

HematúriaHematuria
Muito frequente (99-80%)90%
Laminação difusa da membrana basal glomerularDiffuse glomerular basement membrane lamellation
Muito frequente (99-80%)90%
Membrana basal glomerular finaThin glomerular basement membrane
Muito frequente (99-80%)90%
Insuficiência renalRenal insufficiency
Frequente (79-30%)55%
HipertensãoHypertension
Frequente (79-30%)55%

Linha do tempo da pesquisa

Publicações por ano — veja quando o interesse científico cresceu
Anos de pesquisa1desde 2026
Total histórico1.971PubMed
Últimos 10 anos200publicações
Pico2025151 papers
Linha do tempo
2026Hoje · 2026🧪 1995Primeiro ensaio clínico📈 2025Ano de pico
Publicações por ano (últimos 10 anos)

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Genética e causas

O que está alterado no DNA e como passa nas famílias

Genes associados

3 genes identificados com associação a esta condição. Padrão de herança: Autosomal dominant, Autosomal recessive, X-linked dominant.

COL4A3Collagen alpha-3(IV) chainDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Type IV collagen is the major structural component of glomerular basement membranes (GBM), forming a 'chicken-wire' meshwork together with laminins, proteoglycans and entactin/nidogen Tumstatin, a cleavage fragment corresponding to the collagen alpha 3(IV) NC1 domain, possesses both anti-angiogenic and anti-tumor cell activity; these two anti-tumor properties may be regulated via RGD-independent ITGB3-mediated mechanisms

LOCALIZAÇÃO

Secreted, extracellular space, extracellular matrix, basement membrane

VIAS BIOLÓGICAS (1)
Collagen degradation
OUTRAS DOENÇAS (6)
hematuria, benign familial, 2Alport syndrome 3b, autosomal recessiveautosomal dominant Alport syndromeautosomal recessive Alport syndrome
HGNC:2204UniProt:Q01955
COL4A4Collagen alpha-4(IV) chainDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Type IV collagen is the major structural component of glomerular basement membranes (GBM), forming a 'chicken-wire' meshwork together with laminins, proteoglycans and entactin/nidogen

LOCALIZAÇÃO

Secreted, extracellular space, extracellular matrix, basement membrane

VIAS BIOLÓGICAS (2)
Collagen biosynthesis and modifying enzymesCollagen chain trimerization
MECANISMO DE DOENÇA

Alport syndrome 2, autosomal recessive

A syndrome characterized by progressive glomerulonephritis, glomerular basement membrane defects, renal failure, sensorineural deafness and specific eye abnormalities (lenticonous and macular flecks). The disorder shows considerable heterogeneity in that families differ in the age of end-stage renal disease and the occurrence of deafness.

OUTRAS DOENÇAS (4)
hematuria, benign familial, 1autosomal recessive Alport syndromedigenic Alport syndromeautosomal dominant Alport syndrome
HGNC:2206UniProt:P53420
COL4A5Collagen alpha-5(IV) chainDisease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Type IV collagen is the major structural component of glomerular basement membranes (GBM), forming a 'chicken-wire' meshwork together with laminins, proteoglycans and entactin/nidogen

LOCALIZAÇÃO

Secreted, extracellular space, extracellular matrix, basement membrane

VIAS BIOLÓGICAS (2)
Collagen biosynthesis and modifying enzymesCollagen chain trimerization
MECANISMO DE DOENÇA

Alport syndrome 1, X-linked

A syndrome that is characterized by progressive glomerulonephritis, renal failure, sensorineural deafness, specific eye abnormalities (lenticonous and macular flecks), and glomerular basement membrane defects. The disorder shows considerable heterogeneity in that families differ in the age of end-stage renal disease and the occurrence of deafness.

OUTRAS DOENÇAS (3)
X-linked Alport syndromedigenic Alport syndromeX-linked diffuse leiomyomatosis-Alport syndrome
HGNC:2207UniProt:P29400

Medicamentos e terapias

HYDROXYCHLOROQUINEPhase 2

Mecanismo: Toll-like receptor 7 antagonist

BENAZEPRILPhase 2

Mecanismo: Angiotensin-converting enzyme inhibitor

VALSARTANPhase 2

Mecanismo: Type-1 angiotensin II receptor antagonist

BARDOXOLONE METHYLPhase 2

Mecanismo: Keap1/Nrf2 inhibitor

FLUVASTATINPhase 2

Mecanismo: HMG-CoA reductase inhibitor

ELX-02Phase 2

Mecanismo: 80S Ribosome modulator

Ver mais no OpenTargets

Variantes genéticas (ClinVar)

4,079 variantes patogênicas registradas no ClinVar.

🧬 COL4A3: NM_000091.5(COL4A3):c.866del (p.Ala289fs) ()
🧬 COL4A3: NM_000091.5(COL4A3):c.3656G>A (p.Gly1219Asp) ()
🧬 COL4A3: NM_000091.5(COL4A3):c.888+1G>C ()
🧬 COL4A3: NM_000091.5(COL4A3):c.3619G>T (p.Gly1207Trp) ()
🧬 COL4A3: NM_000091.5(COL4A3):c.546+2T>G ()
Ver todas no ClinVar

Classificação de variantes (ClinVar)

Distribuição de 4,062 variantes classificadas pelo ClinVar.

1219
2843
Patogênica (30.0%)
VUS (70.0%)
VARIANTES MAIS SIGNIFICATIVAS
COL4A5: NM_033380.3(COL4A5):c.1587+6T>G [Pathogenic]
COL4A3: NM_000091.5(COL4A3):c.888+1G>C [Pathogenic]
COL4A3: NM_000091.5(COL4A3):c.3619G>T (p.Gly1207Trp) [Likely pathogenic]
COL4A3: NM_000091.5(COL4A3):c.546+2T>G [Pathogenic]
COL4A3: NM_000091.5(COL4A3):c.3202G>T (p.Gly1068Ter) [Likely pathogenic]

Diagnóstico

Os sinais que médicos procuram e os exames que confirmam

Carregando...

Tratamento e manejo

Remédios, cuidados de apoio e o que precisa acompanhar

Pipeline de tratamentos
Pipeline regulatório — de medicamentos já aprovados a drogas em pesquisa exploratória.
Aprovado1
3Fase 31
2Fase 214
·Pré-clínico10
Medicamentos catalogadosEnsaios clínicos· 6 medicamentos · 20 ensaios
Carregando informações de tratamento...

Onde tratar no SUS

Hospitais de referência no Brasil e o protocolo oficial do SUS (PCDT)

🇧🇷 Atendimento SUS — Síndrome Alport

🗺️

Selecione um estado ou use sua localização para ver resultados.

Dados de DATASUS/CNES, SBGM, ABNeuro e Ministério da Saúde. Sempre confirme a disponibilidade diretamente com o estabelecimento.

Pesquisa ativa

Ensaios clínicos abertos e novidades científicas recentes

🟢 Recrutando agora

9 pesquisas recrutando participantes. Converse com seu médico sobre a possibilidade de participar.

Outros ensaios clínicos

38 ensaios clínicos encontrados, 15 ativos.

Distribuição por fase
Ver todos no ClinicalTrials.gov
🧪 Está conduzindo uma pesquisa?
Divulgue para pacientes e familiares que acompanham esta doença.
Divulgar pesquisa →

Publicações mais relevantes

Timeline de publicações
1.102 papers (10 anos)

Mostrando amostra de 200 publicações de um total de 1.102

#1

Sequential sequencing reveals the architecture and complexity of genomic variants in patients with Alport syndrome.

Nature communications2026 Mar 23

Alport syndrome (AS) is a prevalent inherited kidney disorder mainly caused by mutations in COL4A3, COL4A4, and COL4A5 genes. To elucidate the genetic variants of AS, we implemented a sequential sequencing strategy within a Chinese cohort of 555 patients, comprising whole-exome sequencing (WES) for all participants, followed by whole-genome sequencing (WGS), RNA sequencing (RNA-seq), and nanopore long-read sequencing (NLR-seq) for selected individuals. We identify 431 distinct variants in 509 (91.7%) patients, with 42.2% being novel. Beyond WES, additional sequencing approaches resolve 23 patients with noncoding, copy number, or structural variants. Notably, noncoding variants account for 16.2% of detected variants and exhibit ethnic-specific mutagenesis patterns. More interestingly, NLR-seq uncovers two novel types of structural variants, namely large insertions in intronic regions and complex duplication-inversion variants. This study provides deeper insights into the genetic architecture of AS and proposes a research paradigm for improving the genetic diagnosis of inherited diseases.

#2

Systematic reassessment of reported variants in individuals with suspicion of Alport spectrum disorder reveals a high rate of ambiguous results.

European journal of human genetics : EJHG2026 Mar 18

"Alport spectrum disorder" describes a phenotypically and genotypically multifaceted disease entity encompassing classic autosomal recessive and X-linked Alport syndrome (AS) but also more heterogenous and typically milder, yet not benign, hematuric phenotypes like autosomal dominant AS, formerly also known as thin basement membrane nephropathy (TBMN). Alport spectrum disorder is associated with disease-causing variants in the type IV collagen genes COL4A3, COL4A4 and COL4A5. Variants and genotypes, reported by a genetic diagnostics lab between 2009 and 2014, of 91 index cases with the clinical tentative diagnosis of AS (66/91), TBMN (21/91), or AS/TBMN (not specified further; 4/91), were reassessed based on 2015 ACMG (American College of Medical Genetics and Genomics) criteria and current amendments. 80 different variants, all originally reported as "mutations", and their genotypes have been reassessed (COL4A3: 21/80, COL4A4: 15/80, COL4A5: 44/80). In 10/80 variants, classification changed from disease-causing to variant of uncertain significance (VUS). 69/91 (76%) index cases included in the analysis could be classified as solved. 22/91 (24%) index cases had an ambiguous result either on variant, genotype, or both variant and genotype level. VUS cases had a significantly more limited phenotype (e.g., isolated microscopic hematuria) compared to non-downgraded cases (e.g., additional extrarenal manifestations). Reassessment of variants/genotypes in this study showed a significant reduction in unequivocal genetic diagnoses highlighting variant and genotype interpretation as a dynamic process. Genetic reports of individuals with suspected Alport spectrum disorder, especially those obtained in the pre-ACMG criteria era, should therefore be critically evaluated.

#3

The Importance of Molecular Testing in the Diagnosis of Genetic Syndromes with Chronic Kidney Disease: Genotype-Phenotype Correlations.

International journal of molecular sciences2026 Mar 03

Globally, chronic kidney disease (CKD) affects over 800 million individuals and is characterized by significant genetic complexity. More than 600 genes are associated with hereditary kidney disease, which may manifest as isolated kidney issues or as part of a syndrome that also includes extrarenal manifestations. The aim of this study was to identify genetic variants in a group of ten patients who presented with clinical signs suggestive of genetic syndromes associated with CKD, or who were asymptomatic but had a positive family history of CKD. Extensive genetic testing (targeted gene panels and whole-exome sequencing-WES) identified a mutation in the PKD1 gene in 3 out of 10 cases. In one patient, a known mutation in the PKD2 gene was identified. Another four patients were diagnosed with Alport syndrome: three of these presented with de novo missense mutations in the COL4A5 gene, and one patient had a mutation in the COL4A3 gene. One patient was diagnosed with MODY5, caused by a known mutation in the HNF1B gene, and one patient was diagnosed with Bartter syndrome type 1, resulting from a known mutation in the SLC12A1 gene. We present genotype-phenotype correlations, highlighting the particularities of each patient within their family context. Our findings emphasize the importance of genotype-phenotype correlations in refining diagnosis, personalizing therapeutic management, and providing essential genetic counseling for at-risk relatives.

#4

'Missing' disease-causing variants in Alport syndrome.

Nature reviews. Nephrology2026 Mar 11

Up to 20% of people with clinically suspected Alport syndrome do not have a disease-causing variant identified with genetic testing. Disease-causing changes are 'missing' because the identified variant is of uncertain significance or no suspicious change has been found. A variant of uncertain significance might be resolved after a clinician-laboratory consultation, family segregation studies, functional assays, evidence from large case-control cohorts or review after further genetic and experimental information becomes available. Other explanations for a lack of disease-causing variants include the presence of phenocopies such as IgA nephropathy, technical issues associated with whole-exome sequencing and difficulties in identifying and computationally assessing non-canonical splicing variants, including deep intronic and synonymous changes. Candidate splicing variants might be identified using whole-exome, whole-genome or long-read sequencing, prioritized bioinformatically, and validated with targeted RNA sequencing or splicing assays. People with suspected Alport syndrome but no identified disease-causing variant should be managed as for Alport syndrome while awaiting confirmation of their diagnosis. Missing disease-causing variants are also common in other genetic kidney diseases, and the methods used for their resolution are the same. Our current inability to detect all disease-causing variants means that the contribution of genetic disease is underestimated for kidney phenotypes.

#5

Glomerular basement membrane structural integrity dictates trans-tissue deposition of laminin in the kidney.

Cell reports2026 Feb 18

Basement membranes (BMs) are specialized extracellular matrices (ECMs) essential for tissue structure and function. In non-vertebrates, ECM components can be produced both locally and by distant tissues. In contrast, mammalian ECM has traditionally been considered to originate predominantly from adjacent or tissue-resident cells. The kidney glomerular basement membrane (GBM), composed of laminin-α5β2γ1 and collagen-α3α4α5(IV), is produced by neighboring cells and functions as a filtration barrier. Alport syndrome, a genetic kidney disease, is characterized by GBM structural defects and ectopic laminin-α2 deposition, but the source of this laminin remains unknown. Here, using CRISPR-Cas9 transgenic models, we demonstrated that ectopic laminin-α2 in GBM originates not from local kidney cells but from the circulation. Furthermore, laminin-α2 in the mesangium partially derives from circulating sources even under healthy conditions. Our findings uncover a non-cell-autonomous mechanism whereby GBM integrity regulates circulating protein incorporation, revealing a trans-tissue regulation of BM composition in mammals.

Publicações recentes

Ver todas no PubMed

📚 EuropePMC1.259 artigos no totalmostrando 197

2026

Sequential sequencing reveals the architecture and complexity of genomic variants in patients with Alport syndrome.

Nature communications
2026

Extracellular vesicle miR-93-5p cargo regulates glomerular endothelial cell damage in Alport syndrome.

JCI insight
2026

Update on Alport Syndrome: The Report of the 2024 International Workshop on Alport Syndrome.

Kidney international reports
2026

Systematic reassessment of reported variants in individuals with suspicion of Alport spectrum disorder reveals a high rate of ambiguous results.

European journal of human genetics : EJHG
2025

Coexisting genetic kidney disease explains many cases of 'familial' IgA nephropathy where the proband has biopsy-confirmed mesangial IgA deposits.

Frontiers in medicine
2026

The Importance of Molecular Testing in the Diagnosis of Genetic Syndromes with Chronic Kidney Disease: Genotype-Phenotype Correlations.

International journal of molecular sciences
2026

'Missing' disease-causing variants in Alport syndrome.

Nature reviews. Nephrology
2026

Heterozygous X-linked Alport syndrome in a pregnant woman: A case report.

SAGE open medical case reports
2026

Alport syndrome complicated with IgA nephropathy: a case report.

Frontiers in medicine
2026

Multifactorial Predictors of Renal Outcomes in Alport Syndrome: Integrating Genetic, Clinical, and Cystic Phenotypes.

Kidney medicine
2026

The Inheritance Puzzle: A Case of Dual Genetic Kidney Disease.

Nephrology (Carlton, Vic.)
2026

Minnelide ameliorates Col4a5+/- mice by upregulating Col4a5 and alleviating endoplasmic reticulum stress.

Frontiers in pharmacology
2026

Screening for genetic kidney diseases in a dialysis cohort via exome sequencing.

Clinical kidney journal
2026

Glomerular basement membrane structural integrity dictates trans-tissue deposition of laminin in the kidney.

Cell reports
2026

Pediatric Conditions for Which Skin Biopsies of Clinically Normal Skin Have Diagnostic Yield: A Review for the Pediatric Dermatologist.

Pediatric dermatology
2026

Not So Normal Skin: A Review of the "Random" Skin Biopsy.

The American Journal of dermatopathology
2026

Hereditary Myopathy With Early Respiratory Failure Associated With an Incidental COL4A5 Variant: A Case Report.

Case reports in genetics
2026

Protective role of early Tnfsf15 upregulation in limiting glomerular injury and proteinuria in experimental Alport Syndrome.

Journal of pharmacological sciences
2026

WNK1 Kinase Activity Is Required for the Functional Maintenance of Podocyte Structure.

FASEB journal : official publication of the Federation of American Societies for Experimental Biology
2026

Case Report: Neuroretinitis versus hypertensive retinopathy secondary to Alport syndrome.

Frontiers in neurology
2026

mRNA Therapy for Alport Syndrome.

bioRxiv : the preprint server for biology
2026

Determining Genetic Cause of Posterior Staphylomas in Eyes with Pathologic Myopia by Whole Exome Sequencing.

Ophthalmology science
2025

Disease-modifying effects of iron deficiency in mouse models of chronic renal failure.

Blood. Red cells &amp; iron
2026

Intravenous trimethoprim-sulfamethoxazole desensitization as a therapeutic strategy for late-onset Pneumocystis jirovecii pneumonia in a kidney transplant recipient: a case report.

Journal of medical case reports
2026

Redefining Alport syndrome in the era of genomic medicine: time for a unified, genotype-driven nomenclature.

Pediatric nephrology (Berlin, Germany)
2026

TRPC6 inhibition for the treatment of focal segmental glomerulosclerosis: a randomised, placebo-controlled, phase 2 trial of BI 764198.

Lancet (London, England)
2026

Deciphering the complexity: a case of kidney failure with co-inheritance of COL4A5 and APOE variants.

BMC nephrology
2025

Modulation of the Apolipoprotein M/S1PR4 Pathway Reduces Podocyte Lipid Overload in Alport Syndrome via Distinct Autophagy and Efflux Mechanisms.

Journal of the American Society of Nephrology : JASN
2025

When Genes Reveal the Truth: Alport Syndrome Mimicking Steroid-Resistant Nephrotic Syndrome.

Pediatric reports
2026

Coincidence of autosomal dominant polycystic kidney disease and Alport syndrome: a case report and literature review.

CEN case reports
2026

Retinal and microvascular alterations in Alport syndrome: a multimodal imaging study.

BMC ophthalmology
2026

Tips of family history taking in diagnosing Alport syndrome: a report of six cases.

CEN case reports
2026

Alport Syndrome is a Partial Tubulointerstitial Disease of the Kidney.

Kidney international reports
2026

Bilateral giant macular holes in a patient with Alport syndrome.

Eye (London, England)
2025

Coexistence of Alport Syndrome and Fabry Disease in a Female with R112H Variant: Early Progression of Fabry Nephropathy.

International journal of molecular sciences
2026

Dapagliflozin Reduces Kidney Inflammation in Alport Syndrome by Inhibiting the Stimulator of Interferon Genes Pathway in Renal Tubular Epithelial Cells.

Kidney360
2026

Whole-genome sequencing identified a deep intronic COL4A5 variant causing aberrant splicing in a female patient with X-linked Alport syndrome.

CEN case reports
2026

A Western Diet High in Phosphate Primes the Development of the CKD-Mineral Bone Disorder in an Alport Syndrome Model.

Kidney360
2025

Shunt Complications in Syndromic versus Non-Syndromic Pediatric Hydrocephalus: A Propensity-Matched Multicenter Analysis of 35,234 Patients.

Pediatric neurosurgery
2025

Urine Screening for Early Diagnosis of Young Individuals With Alport Syndrome: A Call for Action.

Kidney international reports
2025

Impact of Age-3 Urine Screening on Diagnosis and Treatment Timing in Alport Syndrome.

Kidney international reports
2025

Anticodon-edited tRNA enables translational readthrough of COL4A5 premature termination codons.

PloS one
2026

Splice modulation of COL4A5 reinstates collagen IV assembly in an organoid model of Alport syndrome.

JCI insight
2025

A novel COL4A5 splicing variant in alport syndrome presenting with extreme myopia.

Ophthalmic genetics
2025

Clinical features of hearing loss and genotype-phenotype correlations in Alport syndrome caused by COL4A4 or COL4A5 variants.

Scientific reports
2025

Increased in vivo transduction of AAV-9 cargo in Alport podocytes.

Wellcome open research
2025

Electron Microscopy in Renal Biopsy Interpretation: When and Why It Still Matters.

Cureus
2026

Exome Sequencing in a Large Cohort with Ciliopathy-Related Kidney Disease.

Clinical journal of the American Society of Nephrology : CJASN
2025

Alport Syndrome: A Case of Delayed Diagnosis Through Genetic Testing.

Cureus
2025

Case Report: A novel TTN gene variant and a concurrent rare COL4A4 gene variant in a Chinese patient with dilated cardiomyopathy.

Frontiers in cardiovascular medicine
2025

A case of concurrent Alport syndrome and Nail-patella syndrome posing diagnostic challenge without genetic testing.

BMC nephrology
2025

Leveraging genomic biobanks to enhance genetic testing outcomes for kidney disease.

medRxiv : the preprint server for health sciences
2025

Podocyte specific exon skipping after disease onset improves kidney pathology and function in a mouse model of Alport syndrome.

Scientific reports
2025

Genetic etiology of inherited kidney diseases in egyptian patients: next generation sequencing identifies six novel variants.

Molecular and cellular pediatrics
2026

High adherence to angiotensin-converting enzyme inhibitor in children and adolescents with Alport syndrome: objective verification using liquid chromatography-mass spectrometry.

Pediatric nephrology (Berlin, Germany)
2025

Autosomal Dominant Alport Syndrome Diagnosed in an Elderly Man.

Cureus
2026

From RAAS blockade to regenerative medicine: evolving treatment strategies in Alport syndrome.

Pediatric nephrology (Berlin, Germany)
2025

Dapagliflozin with losartan but not olmesartan has an add-on protective effect in experimental Alport syndrome.

Journal of pharmacological sciences
2026

Bilateral Macular Holes with Depleted Internal Limiting Membrane in Alport Syndrome Patient: A Case Report.

Korean journal of ophthalmology : KJO
2026

Kidney Cysts in Alport Syndrome: Illustrative Cases, but Misleading Conclusions.

American journal of kidney diseases : the official journal of the National Kidney Foundation
2025

Whole-exome sequencing of kidney transplant recipients and donors: insights into end-stage renal disease and post-transplant genetic risk.

BMC nephrology
2025

Kidney organoids in translational research: disease modeling, drug discovery, and unresolved challenges.

Cell and tissue research
2025

Case report: Surgical and clinical results in bilateral lenticonus due to Alport syndrome.

Romanian journal of ophthalmology
2025

Gene Therapies: Any Merit in Nephrology?

Giornale italiano di nefrologia : organo ufficiale della Societa italiana di nefrologia
2026

Mouse Alport podocytes are susceptible to AAV9 transduction in vivo.

Kidney international
2025

Corrigendum to "Discoidin domain receptor 1 activation links extracellular matrix to podocyte lipotoxicity in Alport syndrome" eBioMedicine, Volume 63, January 2021, 103162.

EBioMedicine
2026

Cochlear Implantation in Alport Syndrome: A Novel Case Series.

Otology &amp; neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology
2025

From Data to Drug: The Translational Impact of RaDaR, the UK National Registry of Rare Kidney Diseases.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
2025

Case Report: Evaluation of COL4A5 non-canonical splicing variants in two families.

Frontiers in medicine
2025

Expanding the COL4A4 variant spectrum: genotype-phenotype correlation in 19 Chinese children using updated Alport kidney disease classification.

Renal failure
2025

An Elusive Diagnosis of Autosomal Dominant Alport Syndrome: Genomic Sequencing Is a Game Changer.

Cureus
2025

Nephrotic syndrome as the first symptom in Alport syndrome children.

Clinical nephrology
2025

Long-Term Renal Transplant Success Is Possible in Hypoparathyroidism, Sensorineural Deafness, and Renal Dysplasia Syndrome: A Case Report.

Molecular syndromology
2025

Age at disease onset and risk of chronic kidney disease in patients with heterozygous disease-causing variants in COL4A3 and COL4A4.

Clinical kidney journal
2025

Nutcracker syndrome in an Alport family: a tricky case.

Wiener klinische Wochenschrift
2025

Severe Clinical Phenotype in Alport Syndrome Due to 2 COL4A4 Exon-Skipping Events.

Kidney medicine
2025

Systematic metabolomic study on the plasma and urine of a mouse model of Alport syndrome.

Scientific reports
2025

Dual Renal and Cardiac Phenotypes Associated with Rare Variants Inherited from Both Parents.

Internal medicine (Tokyo, Japan)
2025

Effect of 2-Hydroxypropyl-γ-cyclodextrin on Renal Inflammation in Alport Mouse Model.

Biological &amp; pharmaceutical bulletin
2025

Whole-exome sequencing in pediatric patients with glomerulonephritis.

Frontiers in genetics
2026

From screening to strategy: Clinical implications of COL4A3/COL4A4 variants found in reproductive genetic testing.

European journal of human genetics : EJHG
2025

Unfolding the potential-chemical chaperones in Alport syndrome.

Kidney international
2026

Investigation of clinical and genetic characteristics of Alport syndrome using a national registry in Japan (JP-ALPS).

Clinical and experimental nephrology
2025

Targeted exome sequencing for molecular diagnosis of pediatric Alport syndrome in Southwest China.

Frontiers in genetics
2026

Treatment Approaches for Alport Syndrome.

Journal of the American Society of Nephrology : JASN
2025

CRISPR and gene editing for kidney diseases: where are we?

Clinical kidney journal
2025

A rare case of dual glomerular pathology: Alport syndrome and immune complex-mediated MPGN.

BMC nephrology
2025

Autosomal recessive Alport syndrome should be diagnosed in an m.3243A>G carrier only if a pathogenic COL4A3 variant has been detected.

Internal medicine (Tokyo, Japan)
2025

Novel COL4A3-COL4A5 variants and digenic inheritance in pediatric Alport syndrome from Southwestern China.

Scientific reports
2025

High Prevalence of Autosomal Recessive Alport Syndrome in Roma Population of Eastern Slovakia.

Biomedicines
2025

Pathogenic synonymous variation of the COL4A3 gene causing Alport syndrome comorbid with IgA deposition in a toddler: a case report.

BMC nephrology
2025

Case Report: Whole genome sequencing identifies a novel deep intronic COL4A5 variant of uncertain significance in X-linked Alport syndrome.

Frontiers in pediatrics
2025

Pediatric Renal Transplantation: A 10-Year Single-Center Experience.

Transplantation proceedings
2025

[A case report of Alport syndrome a denovo mosaic variation in the COL4A5 gene].

Zhonghua er ke za zhi = Chinese journal of pediatrics
2025

How does LAMB2 contribute to kidney disease? Insights from a pediatric case.

BMC nephrology
2025

Lipidomics Unveils Critical Lipid Pathway Shifts in Alport Syndrome.

Kidney international reports
2025

Lithuanian Study on COL4A3 and COL4A4 Genetic Variants in Alport Syndrome: Clinical Characterization of 52 Individuals from 38 Families.

International journal of molecular sciences
2025

Gene editing for collagen disorders: current advances and future perspectives.

Gene therapy
2025

Dotinurad, a Novel Urate Reabsorption Inhibitor, Prolongs Survival in Alport Mice.

Kidney360
2025

Alpha-dystroglycan receptor signaling likely influences basement membrane laminin α2 mediated pathology in the stria vascularis of Alport mice.

Hearing research
2025

Co-localization of IgG with nephrin in immune-mediated idiopathic nephrotic syndrome.

Clinical and experimental nephrology
2025

Unveiling Maternal Germline Mosaicism in X-Linked Alport Syndrome by Advanced Genetic Testing.

The American journal of case reports
2025

RNA therapeutics in kidney diseases: prospects and current status.

Clinical kidney journal
2025

Ectopic laminin α2 accumulation in the glomerular basement membrane exacerbates podocyte injury in Alport syndrome.

Biochimica et biophysica acta. Molecular basis of disease
2025

Importance of family history and health checkup for school-aged children for type IV collagen-associated nephropathy in hereditary kidney disease.

Journal of nephrology
2025

Collagen IV in Gould syndrome and Alport syndrome.

Nature reviews. Nephrology
2025

Successful management of a giant macular hole in Alport syndrome using autologous retinal translation as an initial procedure.

Retinal cases &amp; brief reports
2025

Extracellular Matrix: Alport Syndrome.

Advances in experimental medicine and biology
2025

Renal Single-Cell RNA Sequencing and Digital Cytometry in Dogs with X-Linked Hereditary Nephropathy.

Animals : an open access journal from MDPI
2025

Improving the Quality of Two Lives by Treating Obesity.

Reports (MDPI)
2025

Novel mitophagy inducer TJ0113 alleviates pulmonary inflammation during acute lung injury.

Frontiers in pharmacology
2025

Kidney Cysts in Autosomal Dominant Polycystic Kidney Disease and Alport Syndrome: Two Familial Cases Illustrating Diagnostic Challenges.

American journal of kidney diseases : the official journal of the National Kidney Foundation
2025

Estimating Lifetime Risk of Autosomal Recessive Kidney Diseases Using Population-Based Genotypic Data.

Kidney international reports
2025

Educating the Next-Generation Expert in Nephrology Genetics.

Seminars in nephrology
2025

Stair-Case/Honeycomb Maculopathy in Alport Syndrome: A Case Report.

Case reports in ophthalmology
2025

How to Suspect and Approach Patients With Genetic Glomerular Disease.

Seminars in nephrology
2025

Hereditary kidney disease with auditory abnormalities: analysis of mutations and clinical phenotypes.

BMC medical genomics
2025

[Anterior lenticonus in Alport Syndrome].

Die Ophthalmologie
2025

Using Large Genomic Biobanks to Generate Insights into Genetic Kidney Disease.

Seminars in nephrology
2025

A Prediction Model of Disease Progression in X-Linked Alport syndrome Based on Clinical Characteristics and Genetic Variants.

Kidney international reports
2026

Combined Alport Syndrome Type 3A and Mitochondrial Disease Presenting with a Thin Base Membrane and Overt Albuminuria.

Internal medicine (Tokyo, Japan)
2025

Urinary DKK3 in Alport syndrome: early marker or epiphenomenon?

Pediatric nephrology (Berlin, Germany)
2025

A comprehensive splicing characterization of COL4A5 mutations and prognostic significance in a single cohort with X-linked alport syndrome.

Frontiers in genetics
2025

Collagen Type IV Variants and Kidney Cysts: Decoding the COL4A Puzzle.

Genes
2025

Alport syndrome complicated with steroid-sensitive nephrotic syndrome: a case report.

Pediatric nephrology (Berlin, Germany)
2025

Progressive Renal Dysfunction in Autosomal-dominant Alport Syndrome Co-occurring with C1q Nephropathy.

Internal medicine (Tokyo, Japan)
2025

Efficacy of Nrf2 activation in a proteinuric Alport syndrome mouse model.

Life science alliance
2025

Targeted incorporation of collagen IV to the basement membrane: A step forward for developing extracellular protein therapies.

The Journal of biological chemistry
2025

The complexity of kidney disease secondary to collagen IV variants: insights into phenotypic variability from a large Sicilian pedigree.

Journal of nephrology
2025

WNK1 kinase activity is required for maintenance of podocyte foot process structure.

bioRxiv : the preprint server for biology
2025

Dapagliflozin, in addition to ramipril, ameliorates kidney disease progression in mice with Alport syndrome.

American journal of physiology. Renal physiology
2025

Familial Kidney Disease Phenocopying Hypertensive Nephropathy.

Glomerular diseases
2025

The First Observation and Diagnosis of Nail-Patella Syndrome Using LV-SEM: GBM Abnormalities Mimicking Alport Syndrome.

Nephrology (Carlton, Vic.)
2025

Prospective Cohort Study in Alport Syndrome Patients Under Standard Therapy.

Kidney international reports
2025

COL4A5-p.Gly624Asp is the Predominant Variant in Europe Associated With a Mild Alport Syndrome Phenotype.

Kidney international reports
2025

Chemical chaperone 4-phenylbutyrate treatment alleviates the kidney phenotype in a mouse model of Alport syndrome with a pathogenic variant in Col4a3.

Kidney international
2025

Relationship between clinical and pathologic findings and the presence of genetic variants in patients with steroid-resistant nephrotic syndrome.

Pediatric nephrology (Berlin, Germany)
2025

Proteinuria in Alport Syndrome: Treatment With Sodium-Glucose Co-Transporter-2 (SGLT2) Inhibitors.

Cureus
2025

The enzyme SMPDL3b in podocytes decouples proteinuria from chronic kidney disease progression in experimental Alport Syndrome.

Kidney international
2025

The heterozygous mutation COL4A4 c.817-1G>A causes Alport syndrome in a Chinese family: a case report.

Frontiers in pediatrics
2025

A retrospective study of kidney disease in Alport syndrome during and after pregnancy.

Journal of nephrology
2025

A novel mouse model for X-linked Alport syndrome induced by splicing mutation in the Col4a5 gene.

Scientific reports
2025

Kidney pathological findings of MYH9-related disease: a cross-sectional nationwide survey in Japan.

Pediatric nephrology (Berlin, Germany)
2025

[New Genetic Variants Involved in the Pathogenesis of Autosomal Dominant Alport Syndrome: A Familial Case Report].

Giornale italiano di nefrologia : organo ufficiale della Societa italiana di nefrologia
2025

[Renal Lipid Metabolism in Collagenopathies].

Giornale italiano di nefrologia : organo ufficiale della Societa italiana di nefrologia
2025

Carrier screening for Alport syndrome: The clinical importance of heterozygosity for pathogenic or likely pathogenetic variants.

Journal of genetic counseling
2025

Clinical differences between female monozygotic twins with X-linked Alport syndrome with somatic mosaicism.

Pediatric nephrology (Berlin, Germany)
2025

Amniotic membrane grafting in the prevention of long-term retinal detachment secondary to giant full-thickness macular hole in Alport syndrome.

Journal francais d'ophtalmologie
2025

Clinical use of the VNtyper-Kestrel pipeline for MUC1 variant detection in autosomal-dominant tubulointerstitial kidney disease.

Clinical and experimental nephrology
2025

Phenotype-genotype correlations in patients with Alport syndrome from the Polish population.

Journal of nephrology
2025

Are we ACE-ing the early treatment of Alport syndrome?

Pediatric nephrology (Berlin, Germany)
2025

Thiazides as an additional antiproteinuric treatment in young patients with Alport syndrome.

Clinical kidney journal
2025

Corrigendum to A triad of retinal signs in Alport syndrome: The 'stair-case' fovea, choroidal thinning and peripheral schisis.

European journal of ophthalmology
2025

Tacrolimus-Associated Leukoencephalopathy Following a Living Donor Kidney Transplant for Autosomal Recessive Alport Syndrome: A Case Report.

Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation
2025

Collagen IV of basement membranes: I. Origin and diversification of COL4 genes enabling metazoan multicellularity, evolution, and adaptation.

The Journal of biological chemistry
2025

Alport Syndrome Presenting as Incidental Finding of Proteinuria on Pre-Employment Checkup: A Case Report.

Case reports in nephrology
2025

Whole exome sequencing shows novel COL4A3 and COL4A4 variants as causes of Alport syndrome in Rio Grande do Norte, Brazil.

BMC genomics
2025

Systematic Review of Management Strategies for Alport Syndrome: Implications for Male Patients.

Health science reports
2025

Tubular proteinuria due to hereditary endocytic receptor disorder of the proximal tubule: Dent disease and chronic benign proteinuria.

Pediatric nephrology (Berlin, Germany)
2025

The Role of Vitamin D in Rare Diseases-A Clinical Review.

Biomedicines
2025

The interplay between the cardiovascular system and pediatric congenital or acquired kidney diseases.

Pediatric nephrology (Berlin, Germany)
2025

Understanding the clinical genetics of kidney stone disease using the Natera Renasight panel.

Urolithiasis
2025

Keap1-independent Nrf2 regulation: A novel therapeutic target for treating kidney disease.

Redox biology
2025

Increased HA/CD44/TGFβ signaling implicates in renal fibrosis of a Col4a5 mutant Alport mice.

Molecular medicine (Cambridge, Mass.)
2025

Oral Ketone β -Hydroxybutyrate Supplement Retards the Loss of GFR in Alport Mice on Dual Renin-Angiotensin System/Sodium-Glucose Transporter 2 Blockade.

Kidney360
2025

NAD+ prevents chronic kidney disease by activating renal tubular metabolism.

JCI insight
2025

Identification of novel COL4A5 variants and prenatal diagnosis in three large families.

Scientific reports
2025

SGLT2 inhibitors in CKD: are they really effective in all patients?

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
2025

Pathogenic variants in the Alport genes are prevalent in the Singapore multiethnic population with highest frequency in the Chinese.

Scientific reports
2025

Incidence of Leading Causes of Pediatric CKD Using Electronic Health Record-Driven Computable Phenotype.

Kidney360
2025

GLP-1 receptor agonists-another promising therapy for Alport syndrome?

Journal of rare diseases (Berlin, Germany)
2025

Molecular Review of Suspected Alport Syndrome Patients-A Single-Centre Experience.

Genes
2025

Candidate Genetic Modifiers in Alport Syndrome: A Case Series.

Life (Basel, Switzerland)
2025

A CASE REPORT OF TEMPORAL MACULAR THINNING ASSOCIATED WITH ALPORT SYNDROME.

Retinal cases &amp; brief reports
2025

COL4A5 Intronic Variants at Third to Fifth Nucleotides Cause Alport Syndrome.

Kidney international reports
2025

Alport Syndrome May contribute to Grand Multiparity in a Typical Low Income Setting.

Ethiopian journal of health sciences
2025

[Alport syndrome-the most common hereditary glomerular kidney disease].

MMW Fortschritte der Medizin
2025

Renal Phenotype Variations among Families with Autosomal Alport Syndrome: Potential Role of Modifier Genes.

Kidney360
2025

Cracking the code: an integrated electronic medical record approach to early diagnosis of genetic kidney disease in children with microscopic haematuria.

Pediatric nephrology (Berlin, Germany)
2025

Corneal endothelial neovascularization and glaucoma in X-linked Alport syndrome.

European journal of ophthalmology
2025

Effects of a Novel COL4A3 Homozygous/Heterozygous Splicing Mutation on the Mild Phenotype in a Family With Autosomal Recessive Alport Syndrome and a Literature Review.

Molecular genetics &amp; genomic medicine
2025

Case of maternal uniparental isodisomy with autosomal recessive Alport syndrome combined with congenital myasthenia and Oguchi disease.

CEN case reports
2025

A Novel Loss-of-Function Variant in COL4A3 in a Consanguineous Moroccan Family Displaying the Alport Syndrome with Variable Clinical Expression.

Molecular syndromology
2025

Trichostatin A suppresses hearing loss by reducing oxidative stress and inflammation in an Alport syndrome model.

PloS one
2025

Selective endothelin A receptor antagonism in chronic kidney disease: improving clinical application.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
2025

Urinary Dickkopf-related protein 3 as a novel biomarker for kidney function decline in children with Alport syndrome.

Pediatric nephrology (Berlin, Germany)
2025

Genotype-Based Molecular Mechanisms in Alport Syndrome.

Journal of the American Society of Nephrology : JASN
2025

The Impact of a Western Diet High in Phosphate on the CKD-MBD in an Alport Syndrome Model.

bioRxiv : the preprint server for biology
2025

Aberrant right renal perfusion from right internal mammary artery.

Journal of vascular surgery cases and innovative techniques
2025

The role of cyclooxygenase-2 (COX-2) and inflammatory markers in the progress of Alport syndrome in Egyptian children.

BMC pediatrics
2024

Case Report: Nephrotic syndrome as the primary manifestation of Alport syndrome in a Chinese pediatric patient.

Frontiers in pediatrics
2024

Actinomyces odontolyticus: A Rare Agent of Exit-Site Infection in Peritoneal Dialysis.

Cureus
2025

[Clinical and genetic features of persistent asymptomatic microscopic hematuria in children].

Zhonghua er ke za zhi = Chinese journal of pediatrics
2025

Alport syndrome: an update.

Current opinion in nephrology and hypertension
2025

Advances in CRISPR-Cas systems for kidney diseases.

Progress in molecular biology and translational science
2025

Exon location of glycine substitutions impacts kidney survival in autosomal dominant Alport syndrome.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
2025

Unraveling the genetic spectrum of inherited deaf-blindness in Portugal.

Orphanet journal of rare diseases
Ver todos os 1.259 no EuropePMC

Associações

Organizações que acompanham esta doença — pra ter apoio e orientação

Ainda não temos associações cadastradas para Síndrome Alport.

É de uma associação que acompanha esta doença? Fale com a gente →

Comunidades

Grupos ativos de quem convive com esta doença aqui no Raras

Ainda não existe comunidade no Raras para Síndrome Alport

Pacientes, familiares e cuidadores se organizam em comunidades pra compartilhar experiências, fazer perguntas e se apoiar. Você pode ser o primeiro.

Tire suas dúvidas

Perguntas, dicas e experiências compartilhadas aqui na página

Participe da discussão

Faça login para postar dúvidas, compartilhar experiências e interagir com especialistas.

Fazer login

Doenças relacionadas

Doenças com sintomas parecidos — ajudam quem ainda está buscando diagnóstico

Referências e fontes

Bases de dados externas citadas neste artigo

Publicações científicas

Artigos indexados no PubMed ligados a esta doença no grafo RarasNet — título, periódico e PMID direto da fonte, sem intermediação de IA.

  1. Sequential sequencing reveals the architecture and complexity of genomic variants in patients with Alport syndrome.
    Nature communications· 2026· PMID 41872207mais citado
  2. Systematic reassessment of reported variants in individuals with suspicion of Alport spectrum disorder reveals a high rate of ambiguous results.
    European journal of human genetics : EJHG· 2026· PMID 41851263mais citado
  3. The Importance of Molecular Testing in the Diagnosis of Genetic Syndromes with Chronic Kidney Disease: Genotype-Phenotype Correlations.
    International journal of molecular sciences· 2026· PMID 41828581mais citado
  4. 'Missing' disease-causing variants in Alport syndrome.
    Nature reviews. Nephrology· 2026· PMID 41813856mais citado
  5. Glomerular basement membrane structural integrity dictates trans-tissue deposition of laminin in the kidney.
    Cell reports· 2026· PMID 41712384mais citado
  6. Unusual Glomerular Abnormalities in a Patient With Combined COL4A5-NPHS1 Variants.
    Kidney Med· 2026· PMID 41971232recente
  7. Umbilical cord-derived mesenchymal stem cells restore renal homeostasis in Alport Syndrome: Mechanistic insights and clinical translation.
    J Adv Res· 2026· PMID 41951047recente
  8. SPARC upregulation mediates podocyte injury in Alport syndrome mice.
    BMC Nephrol· 2026· PMID 41933297recente
  9. Clinical Insights Into the COL4A3 p.Gly407Arg Variant in Alport Syndrome.
    Kidney360· 2026· PMID 41931366recente
  10. Epidemiological characteristics and treatment patterns of Alport syndrome in Korea.
    Kidney Res Clin Pract· 2026· PMID 41923552recente

Bases de dados e fontes oficiais

Identificadores e referências canônicas usadas para montar este verbete.

  1. ORPHA:63(Orphanet)
  2. MONDO:0018965(MONDO)
  3. GARD:5785(GARD (NIH))
  4. Variantes catalogadas(ClinVar)
  5. Busca completa no PubMed(PubMed)
  6. Artigo Wikipedia(Wikipedia)
  7. Q1331116(Wikidata)

Dados compilados pelo RarasNet a partir de fontes abertas (Orphanet, OMIM, MONDO, PubMed/EuropePMC, ClinicalTrials.gov, DATASUS, PCDT/MS). Este conteúdo é informativo e não substitui avaliação médica.

Conteúdo mantido por Agente Raras · Médicos e pesquisadores podem colaborar

Síndrome Alport
Compêndio · Raras BR

Síndrome Alport

ORPHA:63 · MONDO:0018965
Prevalência
Unknown
Herança
Autosomal dominant, Autosomal recessive, X-linked dominant
CID-10
Q87.8 · Outras síndromes com malformações congênitas especificadas, não classificadas em outra parte
CID-11
Ensaios
15 ativos
Medicamentos
6 registrados
Início
Adolescent, Adult, Childhood, Elderly
Prevalência
0.0 (Europe)
MedGen
UMLS
C0027706
EuropePMC
Wikidata
Wikipedia
Papers 10a
DiscussaoAtiva

Nenhuma novidade ainda. O agente esta monitorando.

0membros
0novidades